Developing Melflufen (Ygalo): alkylating peptide in class of Peptidase Enhanced Compounds targeting MM transformation process, selectively targets MM. MoA overcomes resistance mechanisms for current therapies (iMIDs), demonstrated superior efficacy vs. SOC. Presented interim data at EHA (2018) from ongoing Ph2 HORIZON study in late stage r/r MM showing ORR of ~32%. Ph 3 OCEAN study comparing Ygalo to pomalidomide in late-stage r/r MM, Ph 1/2 ANCHOR study in combo w bortezomib or daratumumab in r/r MM.
Västra Trädgårdsgatan 15
Stockholm, SE-111 53
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by